CN115414391A - Application of lactobacillus plantarum MA2 in preparation of medicine for preventing or improving adenine-induced chronic kidney diseases - Google Patents
Application of lactobacillus plantarum MA2 in preparation of medicine for preventing or improving adenine-induced chronic kidney diseases Download PDFInfo
- Publication number
- CN115414391A CN115414391A CN202211199403.4A CN202211199403A CN115414391A CN 115414391 A CN115414391 A CN 115414391A CN 202211199403 A CN202211199403 A CN 202211199403A CN 115414391 A CN115414391 A CN 115414391A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- adenine
- use according
- chronic kidney
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 122
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 112
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 112
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 54
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229930024421 Adenine Natural products 0.000 title claims abstract description 49
- 229960000643 adenine Drugs 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims description 7
- 241000699670 Mus sp. Species 0.000 claims abstract description 21
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 238000004321 preservation Methods 0.000 claims abstract description 12
- 239000002441 uremic toxin Substances 0.000 claims abstract description 11
- 238000002474 experimental method Methods 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 11
- 206010061481 Renal injury Diseases 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 208000037806 kidney injury Diseases 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 10
- 239000008267 milk Substances 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 244000068988 Glycine max Species 0.000 claims description 9
- 206010024642 Listless Diseases 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 208000017971 listlessness Diseases 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 210000005027 intestinal barrier Anatomy 0.000 claims description 4
- 230000004673 intestinal mucosal barrier function Effects 0.000 claims description 4
- 235000020247 cow milk Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000016261 weight loss Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 46
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 34
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 24
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 24
- 229940116269 uric acid Drugs 0.000 abstract description 24
- 229940109239 creatinine Drugs 0.000 abstract description 23
- 239000004202 carbamide Substances 0.000 abstract description 21
- 229940045136 urea Drugs 0.000 abstract description 21
- 238000012404 In vitro experiment Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 description 26
- 239000000725 suspension Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004162 Claudin-1 Human genes 0.000 description 6
- 108090000600 Claudin-1 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- -1 appearance Chemical compound 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008772 haikun shenxi Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/60—Drinks from legumes, e.g. lupine drinks
- A23L11/65—Soy drinks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of lactobacillus plantarum (Lactobacillus plantarum) MA2 in preparing a medicine or a functional food for preventing or improving adenine-induced chronic kidney diseases, wherein the lactobacillus plantarum is named as follows: MA2, classification name: lactobacillus plantarum with a preservation number: CGMCC No.3005, preservation date: 2009, 4, 9 days, depository: china general microbiological culture Collection center, west Lu No.1 Hospital No.3, beijing, chaoyang, the area of the republic of China. In vitro experiments prove that the lactobacillus plantarum MA2 has the capacity of removing uremic toxins such as creatinine, urea, uric acid and the like, and animal in vivo experiments prove that the adenine-induced chronic kidney diseases of mice can be improved by intragastrically administering the lactobacillus plantarum MA2 and the inactivated strain thereof.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and relates to lactobacillus plantarum MA2, in particular to application of lactobacillus plantarum MA2 in preparation of medicines for preventing or improving adenine-induced chronic kidney diseases.
Background
In recent years, more and more researches prove that the intestinal flora imbalance is closely related to the occurrence of Chronic Kidney Disease (CKD), and the intestinal flora is obviously changed in quantity, composition and proportion, such as the quantity of probiotics including lactobacillus and bifidobacterium is obviously reduced, the quantity of conditional pathogenic bacteria including escherichia coli is obviously increased, and the intestinal flora imbalance can be improved by administering the probiotics, so that the CKD is relieved.
The physiological functions regulated by different probiotics are different and have strain specificity, so that the selection of proper strains for intervention test is most important through the functional characteristics. Lactobacillus plantarum MA2 is a Lactobacillus plantarum separated from Tibetan Kefir grains by professor Wang Yan Liang in laboratory of Probiotics resource development and application of Tianjin science and technology university, and is preserved in the strain preservation center of institute of microbiology of Chinese academy of sciences at 4-9 th 2009 with the preservation number of CGMCC NO.3005. A great number of experiments have proved that l.plantarum MA2 has the effects of regulating intestinal flora, resisting depression and anxiety, reducing cholesterol, resisting oxidation, improving AD and the like by a professor of Wang Yan Lian, and the related research of improving CKD is summarized by the patent application.
So far, reports about the ability of probiotics to metabolize and degrade creatinine, urea nitrogen and uric acid during in vitro culture and show the ability to degrade the creatinine, the urea nitrogen and the uric acid after the animals are gavaged are still few, and the occurrence of the invention has important significance for the adjuvant treatment of kidney injury and the recovery of kidney function.
Through searching, the following patent publications related to the patent application of the invention are found:
1. the lactobacillus plantarum ZDY2013 is applied to preparation of products for relieving kidney injury (CN 112553115A), and the lactobacillus plantarum ZDY2013 is extremely resistant to acid and bile salts, can keep higher survival rate in gastrointestinal fluids, and can inhibit growth of food-borne pathogenic bacteria. In addition, the intestinal flora diversity can be adjusted, so that the gastrointestinal health of a host can be improved. Has the effects of relieving renal fibrosis, improving inflammation appearance symptoms, regulating oxidative stress, regulating and controlling the expression of inflammatory factors and achieving the effect of effectively preventing and treating high-salt diet-induced renal injury.
2. The invention discloses a compound lactobacillus plantarum preparation with a function of reducing blood sugar and application thereof (CN 109136151A), and provides a compound bacterium which consists of lactobacillus plantarum SS18-5 and lactobacillus plantarum SS 18-37. In the compound bacteria, the CFU ratio of the lactobacillus plantarum SS18-5 to the lactobacillus plantarum SS18-37 is 1 (0.01-100). Lactobacillus plantarum SS18-5 with the preservation number of CGMCC No.14917. Lactobacillus plantarum SS18-37 with the preservation number of CGMCC No.14918. The invention also protects the application of the compound bacteria in preparing products; the product is used for treating and/or preventing diabetes. The invention has good effect of reducing blood sugar for diabetes, obviously improves insulin resistance and has protective efficacy for heart, liver, kidney, spleen and pancreas. The invention has wide market application prospect.
By contrast, the present patent application is intrinsically different from the above patent publications.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides the application of the lactobacillus plantarum MA2 in preparing medicines for preventing or improving adenine-induced chronic kidney diseases.
The technical scheme adopted by the invention for solving the technical problem is as follows:
the application of lactobacillus plantarum (Lactobacillus plantarum) MA2 in preparing medicines or functional foods for preventing or improving adenine-induced chronic kidney diseases is characterized in that: MA2, classification name: lactobacillus plantarum with a preservation number: CGMCC No.3005, preservation date: 2009, 4, 9 days, depository: china general microbiological culture Collection center, west Lu No.1 Hospital No.3, beijing, chaoyang, the area of the republic of China.
Further, the lactobacillus plantarum MA2 is a live bacterium or a heat-inactivated strain.
Furthermore, the medicine or functional food takes viable bacteria of the lactobacillus plantarum MA2 or heat inactivated lactobacillus plantarum MA2 as an effective component, and is prepared into a pharmaceutically acceptable dosage form and a food acceptable dosage form.
Further, the dosage form includes tablets, powders, granules, capsules or drinks.
Further, the beverage comprises effective amount of live lactobacillus plantarum MA2 bacteria or heat inactivated lactobacillus plantarum MA2 bacteria and sterile normal saline or dairy products and soybean milk product accessories.
Further, the mass volume concentration of the sterile normal saline is 0.6-0.9%, the dairy product is cow milk, and the soybean milk product is soybean milk.
Further, the characteristics of adenine-induced chronic kidney disease include weight loss, listlessness, kidney damage, renal interstitial fibrosis, body inflammatory reaction, and impaired intestinal mucosal barrier.
Further, the medicine or functional food comprises an effective dose of lactobacillus plantarum MA2 and auxiliary materials acceptable in medicine or food.
Further, the effective amount of the live lactobacillus plantarum MA2 bacteria is 10 9 CFU/day, heat inactivated Lactobacillus plantarum MA2 thallus content 10 9 CFU/day.
Further, the lactobacillus plantarum MA2 can clear away the common uremic toxin and the characteristic of chronic kidney disease when being cultured in vitro;
the lactobacillus plantarum MA2 and the inactivated strain thereof can effectively intervene in treatment and improve chronic kidney diseases of mice in animal experiments.
Further, the common uremic toxins are creatinine, urea, uric acid.
Further, the chronic kidney disease features include weight loss, listlessness, increased permeability of intestinal mucosa, increase of uremic toxins such as creatinine, urea, uric acid, etc. in blood, kidney damage, oxidative stress, renal interstitial fibrosis, etc.
The invention has the advantages and positive effects that:
1. in-vitro experiments prove that the lactobacillus plantarum MA2 has the capacity of removing uremic toxins such as creatinine, urea, uric acid and the like, and animal in-vivo experiments show that the lactobacillus plantarum MA2 and the inactivated strain thereof for intragastric administration can improve mice chronic kidney diseases induced by adenine, including appearance, weight, mental state, kidney injury, inflammatory reaction, intestinal mucosa barrier permeability and the like. The invention finds a new application of lactobacillus plantarum MA2 (Lactobacillus plantarum MA 2), particularly relates to a new application of the lactobacillus plantarum MA2 in improvement of chronic kidney diseases, and provides a new method and a new means for intervention treatment of the chronic kidney diseases by high-quality probiotics.
2. The invention takes the viable lactobacillus plantarum MA2 as an effective component by an in vitro culture method, prepares a formulation acceptable in medicine or food, respectively adds the viable lactobacillus plantarum MA2 into artificial intestinal juice containing creatinine, urea and uric acid, mixes the viable lactobacillus plantarum MA2 in a shaker, observes the utilization capacity of the lactobacillus plantarum MA2 on the creatinine, the urea and the uric acid, and has the following results: l. plantarum MA2 can obviously utilize uremic toxins such as creatinine, urea, uric acid and the like in vitro.
The invention observes and measures the influence of the medical or food-acceptable formulation prepared by taking viable lactobacillus plantarum MA2 (or heat-inactivated lactobacillus plantarum MA 2) as an effective component on the weight, the appearance form, the kidney organ index, the kidney injury, the renal interstitial fibrosis, the expression of inflammatory factors and the intestinal epithelial cell barrier injury of a CKD mouse model by constructing an adenine-induced chronic kidney disease mouse model and finding out the following results: l. plantarum MA2 and the inactivated strain thereof can obviously improve the appearance and the body weight of mice.
The test results prove that the lactobacillus plantarum MA2 viable bacteria are used as effective components and prepared into a pharmaceutically or food acceptable dosage form, the lactobacillus plantarum MA2 viable bacteria not only have the effect of removing common uremic toxins such as creatinine urea, uric acid and the like during in vitro culture, but also can significantly improve the growth inhibition, listlessness, kidney injury, renal interstitial fibrosis, inflammatory reaction and intestinal mucosa permeability brought by adenine-induced chronic kidney diseases by animal experiments, and provide theoretical basis for clinical research on applying probiotics and postbiotic intervention to treat the chronic kidney diseases.
3. The invention provides a medicament or functional food for preventing or improving chronic kidney diseases, which is prepared by using lactobacillus plantarum MA2 in preparing the medicament or functional food for preventing or improving the chronic kidney diseases induced by adenine, has no side effect, and can be used as a safe substitute medicament for treating the chronic kidney diseases in a conventional way.
Drawings
FIG. 1 is a kidney morphology map of each group of mice in the invention (wherein, from left to right, control (blank group), model (Model group), positive drug group, MA2 (Lactobacillus plantarum MA2 group), inactive MA2 (heat-inactivated Lactobacillus plantarum MA2 group)) are sequentially shown;
FIG. 2 is a pathological observation picture of the kidney of each group of mice in the invention (Control (blank group): lavage normal saline, model (Model group): lavage adenine suspension, positive drug group): lavage adenine suspension and positive drug, MA2 (Lactobacillus plantarum MA2 group): lavage adenine suspension and Lactobacillus plantarum MA2 bacterial liquid, inactive MA2 (heat-inactivated Lactobacillus plantarum MA2 group): lavage adenine suspension and heat-inactivated Lactobacillus plantarum MA2 bacterial liquid);
FIG. 3 is a bar graph showing the relative expression levels of IL-1. Beta. In the kidney inflammation-related factor in each group of mice according to the present invention (data are mean. + -. S.D; compared with the blank group, ## p is less than 0.01; p < 0.05, p < 0.05 compared to model group; control (blank Control): normal saline for gastric perfusion; model (Model set): filling gastric adenine suspension; postive (positive drug group): intragastric adenine suspension and positive drug; MA2 (lactobacillus plantarum MA2 group): infusing adenine suspension and Lactobacillus plantarum MA2 bacterial liquid; inactive MA2 (heat inactivated lactobacillus plantarum MA2 group): filling gastric adenine suspension and heat-inactivated lactobacillus plantarum MA2 bacterial liquid);
FIG. 4 is a graph showing the results of relative expression of claudin-1 protein in colon and LPS content in kidney of each group of mice in the present invention (A: claudin-1, B; data are mean values. + -. S.D; compared with the Model group, p < 0.01 control (blank control group) gavage physiological saline, model (Model group) gavage adenine suspension, positive (Positive drug group) gavage adenine suspension and positive drug, MA2 (Lactobacillus plantarum MA2 group) gavage adenine suspension and Lactobacillus plantarum MA2 bacterial solution, inactive MA2 (Heat inactivated Lactobacillus plantarum MA2 group) gavage adenine suspension and Heat inactivated Lactobacillus plantarum MA2 bacterial solution);
FIG. 5 is a bar graph showing the activity of enzymes related to the degree of oxidative stress in the kidney of each group of mice according to the present invention (A: GSH-PX, B: MDA; data are mean. + -. S.D; compared with the blank group, ## p is less than 0.01; p < 0.05, p < 0.01 as compared to model group; control (blank Control): perfusing stomach with normal saline; model (Model set): filling gastric adenine suspension; postive (positive drug group): intragastric adenine suspension and positive drug; MA2 (lactobacillus plantarum MA2 group): infusing adenine suspension and Lactobacillus plantarum MA2 bacterial liquid; inactive MA2 (heat inactivated lactobacillus plantarum MA2 group): gastric adenine infusion suspension and heat inactivated lactobacillus plantarum MA2 bacterial liquid).
Detailed Description
The present invention is further illustrated by the following examples, which are intended to be illustrative, not limiting and are not intended to limit the scope of the invention.
The various experimental procedures described in the specific examples are conventional in the art and are not specifically described herein, and one of ordinary skill in the art can refer to various conventional tool books, scientific literature, or related specifications, manuals, etc. before the filing date of the present application.
The application of lactobacillus plantarum (Lactobacillus plantarum) MA2 in preparing medicines or functional foods for preventing or improving adenine-induced chronic kidney diseases is characterized in that: MA2, classification name: lactobacillus plantarum, with the deposit number: CGMCC No.3005, preservation date: 2009, 4, 9 days, depository: china general microbiological culture Collection center, hospital No.3 of West Lu No.1, on the North of the Chao Yang district, beijing, china.
Preferably, the lactobacillus plantarum MA2 is a live bacterium or a heat-inactivated strain.
Preferably, the medicament or the functional food takes the live lactobacillus plantarum MA2 bacteria or the heat inactivated lactobacillus plantarum MA2 as an effective component and is prepared into a pharmaceutically acceptable dosage form and a food.
Preferably, the dosage form comprises a tablet, a powder, a granule, a capsule or a drink.
Preferably, the drink comprises effective dose of live lactobacillus plantarum MA2 bacteria or heat inactivated lactobacillus plantarum MA2 and sterile normal saline or auxiliary materials of dairy products and soybean milk products.
Preferably, the mass volume concentration of the sterile normal saline is 0.6-0.9%, the dairy product is cow milk, and the soybean milk product is soybean milk.
Preferably, the characteristics of adenine-induced chronic kidney disease include weight loss, listlessness, kidney damage, renal interstitial fibrosis, body inflammatory response, and impaired intestinal mucosal barrier.
Preferably, the medicine or functional food comprises the lactobacillus plantarum MA2 with effective dose and auxiliary materials acceptable in medicine or food.
Preferably, the effective amount of the live lactobacillus plantarum MA2 bacteria is 10 9 CFU/day, heat inactivated Lactobacillus plantarum MA2 thallus content 10 9 CFU/day.
Preferably, the lactobacillus plantarum MA2 can clear away the common uremic toxins and characteristics of chronic kidney diseases when being cultured in vitro;
the lactobacillus plantarum MA2 and the inactivated strain thereof can effectively intervene in treatment and improve chronic kidney diseases of mice in animal experiments.
Preferably, the common uremic toxins are creatinine, urea, uric acid.
Preferably, the chronic kidney disease is characterized by weight loss, listlessness, increased permeability of intestinal mucosa, increased uremic toxins such as creatinine, urea, uric acid and the like in blood, kidney damage, oxidative stress, renal interstitial fibrosis and the like.
Specifically, the preparation and detection are as follows:
biological preservation description:
the lactobacillus plantarum MA2 used in the invention is preserved in the common microorganism center of China Committee for Culture Collection of Microorganisms (CCM) at 9.4.2009, the address is No.3 of Xilu No.1 of Beijing, chaoyang, and the preservation number is CGMCC NO.3005. And the lactobacillus plantarum MA2 is a known strain disclosed in the prior art, for example, in patent publication CN 103355620A.
Example 1
Weighing Lactobacillus plantarum MA2 powder, dissolving in 1mL edible solute with concentration of 10 9 CFU, or taking Lactobacillus plantarum MA2 powder, dissolving it in 1mL edible solute with concentration of 10 9 And (3) inactivating the CFU at the temperature of 121 ℃ for 20min under high pressure to obtain the sample for preventing or improving the chronic kidney disease.
Example 2
The samples for preventing or improving chronic kidney diseases without heat inactivation described in example 1 were added to the artificial intestinal juice containing creatinine, subjected to shaking table reaction at 37 ℃ and 150r/min for 6 hours, then centrifuged at 4 ℃ and 8000r/min for 20 minutes, and the supernatant was collected and subjected to alkaline picric acid to detect the creatinine content in the supernatant, and the results are shown in table 1, in which the creatinine content in the artificial intestinal juice of MA2 group was significantly reduced by 6.53% as compared to the control group.
TABLE 1 in vitro Creatinine degradation ability of Lactobacillus plantarum MA2
Note: p < 0.01 compared to control
Example 3
The sample for preventing or improving chronic kidney diseases without heat inactivation, which is described in example 1, was added to the artificial intestinal juice containing urea, the mixture was subjected to shaking table reaction at 37 ℃ and 150r/min for 6 hours, then centrifuged at 4 ℃ and 8000r/min for 20 minutes, the supernatant was collected, and finally the urea content in the supernatant was detected using a urea detection kit (urease bosch colorimetry), and the results are shown in table 2, in which the urea content in the artificial intestinal juice of MA2 group was significantly reduced by 12.9% compared to the control group.
TABLE 2 Lactobacillus plantarum MA2 ability to degrade urea in vitro
Note: p < 0.05 compared to control group
Example 4
The sample for preventing or improving chronic kidney disease without heat inactivation described in example 1 was added to the artificial intestinal juice containing uric acid, shaking-bed reaction was carried out at 37 ℃ and 150r/min for 6 hours, then centrifugation was carried out at 4 ℃ and 8000r/min for 20 minutes, and the supernatant was collected and finally the uric acid content in the supernatant was measured using a uric acid kit (uricase colorimetric method), and the results are shown in table 3, in which the uric acid content in the artificial intestinal juice of the MA2 group was significantly reduced by 8% as compared to the control group.
TABLE 3 Lactobacillus plantarum MA2 in vitro uric acid degradation ability
Note: p < 0.05 compared to control group
Examples 2 to 4 adopt in vitro experiments, which show that Lactobacillus plantarum MA2 has the ability to significantly degrade creatinine, urea, and uric acid in vitro.
Example 5
SPF-grade 7-week BALB/C male mice (body weight about 20-23 g) were used as experimental materials and randomizedDivided into 4 groups of 10, each group treated as follows: continuously gavage aseptic normal saline (the mass volume concentration of the sterile normal saline is 0.85%) for 6 weeks in a blank control group; model group: performing continuous gavage with adenine/body weight of 100mg/kg adenine for 6 weeks; l. plantarum MA2 group: a sample for preventing or improving chronic kidney disease (administered 1 time a day at 1X 10 times per administration) without heat inactivation as described in example 1 was administered to a stomach with adenine/body weight of 100mg/kg continuously 9 CFU) 6 weeks; inactive L.plantarum MA2 group was administered by continuous gavage of 100mg/kg adenine per body weight and heat-inactivated samples for preventing or improving chronic kidney disease as described in example 1 (1 time daily, 1X 10 dose each time) 9 CFU) 6 weeks. Mice were weighed once a week and observed to record changes in appearance morphology according to table 4, and mice were dissected for the last week, observed for kidney morphology and weighed.
TABLE 4 Scoring methods
Body weight change, appearance morphology, and kidney morphology and kidney index score during the mice experiment, where kidney morphology is shown in figure 1. The results show that the weight of the mice is recovered, the vertical appearance is relieved, the mental state is improved and the renal edema is relieved after the L.plantarum MA2 and the inactivated strain thereof are subjected to intragastric administration, which shows that the L.plantarum MA2 and the inactivated strain thereof can obviously improve the growth inhibition, the vertical appearance, the listlessness and the renal edema caused by the adenine-induced chronic kidney diseases.
Example 6
Male BALB/C mice (body weight about 20-23 g) of 7 weeks of SPF grade, were randomized into 4 groups of 10 mice each, and the treatment of each group was as follows: continuously gavage aseptic normal saline (the mass volume concentration of the sterile normal saline is 0.85%) for 6 weeks in a blank control group; model group: pressing glandGavage is continued in a purine/body weight mode for 6 weeks with 100mg/kg adenine; positive drug group: continuously performing intragastric administration of 100mg/kg adenine and administration of 200mg/kg Haikun Shenxi Capsule according to adenine/body weight mode; l. plantarum MA2 group: gavage 100mg/kg adenine continuously per adenine/body weight and the drug for preventing or improving chronic kidney disease described in example 1 (1 time daily, 1X 10 dose per time) 9 CFU) 6 weeks; inactive L.plantarum MA2 group was continuously gavaged with 100mg/kg adenine in adenine/body weight manner and administered with the heat-inactivated sample for preventing or improving chronic kidney disease described in example 1 (1 time daily, 1X 10 doses each time) 9 CFU) 6 weeks. Mice were dissected for the last week and serum, kidney, colon were collected.
The enzyme-linked immunosorbent assay kit IS adopted to detect the levels of creatinine, urea, uric acid, IS, pCS and TMAO in mouse serum, and the result shows that compared with a blank group, the adenine suspension induction obviously increases the levels of creatinine, urea, uric acid, IS, pCS and TMAO in mouse serum in a CKD model group, namely 345%, 255%, 124%, 122%, 70.84% and 96.64%, respectively, and after the intervention treatment of lactobacillus plantarum MA2, the levels of the creatinine, the urea, the uric acid, the IS, pCS and TMAO are obviously reduced, namely 38.97%, 42.29%, 28.57%, 39.63%, 28.90% and 40.84%, respectively; after intervention and treatment of heat inactivated lactobacillus plantarum MA2, the levels of serum creatinine, urea, uric acid, IS, pCS and TMAO are remarkably reduced to 28.57%, 28.64%, 18.12%, 37.58%, 31.57% and 37.33%, respectively. It IS demonstrated that Lactobacillus plantarum MA2 and its inactivated strain can alleviate CKD by degrading creatinine, urea nitrogen, uric acid, IS, pCS, TMAO.
The degree of kidney injury and renal interstitial fibrosis were observed by HE staining and Masson staining, respectively, and the results are shown in fig. 2. Fig. 2 shows that compared with the blank group, the kidney of the mouse model group has obvious renal tubular dilatation, vacuolation, renal interstitial fibrosis and collagen fiber deposition, and after intervention and treatment by lactobacillus plantarum MA2 and an inactivated strain thereof, the phenomena of renal fibrosis, renal tubular dilatation and the like of the mouse model CKD are obviously improved, which indicates that intervention by lactobacillus plantarum MA2 and an inactivated strain thereof can reduce kidney injury and relieve renal interstitial fibrosis and renal cell apoptosis.
The real-time fluorescent quantitative PCR detection shows that the expression of the inflammatory factor IL-1 beta in the kidney tissue is shown in figure 3. FIG. 3 shows that the relative expression level of IL-1 beta in the kidney of the mouse model group is significantly increased compared with that of the blank group, and the relative expression level of IL-1 beta in the kidney of the CKD mouse model is significantly decreased after intervention treatment by Lactobacillus plantarum MA2 and an inactivated strain thereof, which indicates that Lactobacillus plantarum MA2 and an inactivated strain thereof can effectively improve the kidney inflammatory response triggered by adenine-induced CKD mouse model so as to prolong the kidney function of the CKD mouse.
The expression of the claudin-1 protein in the colon tissue is detected by real-time fluorescent quantitative PCR and the content of LPS is detected by a mouse LPS ELISA kit, and the result is shown in figure 4. FIG. 4 shows that the relative expression level of claudin-1 protein in colon of mice in model group is significantly reduced, after intervention treatment by Lactobacillus plantarum MA2 and its inactivated strain, the relative expression level of claudin-1 protein in colon of CKD mice is significantly increased, and LPS content is reduced, which indicates that Lactobacillus plantarum MA2 and its inactivated strain can restore the integrity of adenine-induced intestinal mucosal barrier of CKD mice model by increasing the relative expression level of claudin-1 protein, thereby reducing LPS entering blood circulation.
The enzyme-linked immunosorbent assay kit is adopted to detect the activity of GSH-PX and MDA in the kidney of the mouse, and the result is shown in figure 5. Figure 5 shows that compared with the blank group, the GSH-PX activity in the kidney of the mouse model group is obviously reduced, the MDA activity is obviously increased, after intervention and treatment by the lactobacillus plantarum MA2 and the inactivated strain thereof, the GSH-PX activity in the kidney of the CKD mouse model is obviously increased, and the MDA activity is obviously reduced. The lactobacillus plantarum MA2 and the inactivated strain thereof can improve the oxidative stress degree of an adenine-induced CKD mouse model to relieve CKD by regulating the activity of GSH-PX and MDA in the kidney.
And (4) conclusion: according to characterization indexes such as appearance form, body weight, kidney form and kidney index of a mouse, physiological and biochemical indexes such as creatinine, urea and uric acid levels in serum, relative expression levels of inflammatory factors in the kidney and permeability of an intestinal mucosa barrier, the L.plantarum MA2 and the inactivated strain thereof can obviously reduce adverse effects such as weight loss, listlessness, kidney injury, renal interstitial fibrosis and inflammatory reaction caused by adenine-induced chronic kidney diseases, and provide a basis for clinical treatment of the kidney injury.
Although the embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that: various substitutions, changes and modifications are possible without departing from the spirit and scope of the invention and the appended claims, and therefore the scope of the invention is not limited to the embodiments disclosed.
Claims (10)
1. The application of lactobacillus plantarum (Lactobacillus plantarum) MA2 in preparing medicines or functional foods for preventing or improving adenine-induced chronic kidney diseases is described as follows: MA2, classification name: lactobacillus plantarum with a preservation number: CGMCC No.3005, preservation date: 2009, 4, 9 days, depository: china general microbiological culture Collection center, west Lu No.1 Hospital No.3, beijing, chaoyang, the area of the republic of China.
2. Use according to claim 1, characterized in that: the lactobacillus plantarum MA2 is a viable bacterium or a heat inactivated strain.
3. Use according to claim 1, characterized in that: the medicine or functional food takes viable bacteria of the lactobacillus plantarum MA2 or heat inactivated lactobacillus plantarum MA2 as an effective component, and is prepared into a dosage form acceptable in medicine and food.
4. Use according to claim 3, characterized in that: the preparation comprises tablets, powder, granules, capsules or drinks.
5. Use according to claim 4, characterized in that: the beverage comprises effective dose of live lactobacillus plantarum MA2 bacteria or heat inactivated lactobacillus plantarum MA2 and sterile normal saline or milk products and soybean milk product auxiliary materials.
6. Use according to claim 5, characterized in that: the mass volume concentration of the sterile normal saline is 0.6-0.9%, the dairy product is cow milk, and the soybean milk product is soybean milk.
7. Use according to claim 1, characterized in that: the characteristics caused by adenine-induced chronic kidney disease include weight loss, listlessness, kidney injury, renal interstitial fibrosis, body inflammatory reaction, and impaired intestinal mucosal barrier.
8. Use according to claim 1, characterized in that: the medicine or functional food comprises effective dose of lactobacillus plantarum MA2 and auxiliary materials acceptable in medicine or food.
9. Use according to claim 8, characterized in that: the effective amount of the lactobacillus plantarum MA2 viable bacteria is 10 9 CFU/day, heat inactivated Lactobacillus plantarum MA2 thallus content 10 9 CFU/day.
10. Use according to any one of claims 1 to 9, characterized in that: the lactobacillus plantarum MA2 can clear away common uremic toxins and chronic nephropathy when being cultured in vitro;
the lactobacillus plantarum MA2 and the inactivated strain thereof can effectively intervene in treatment and improve chronic kidney diseases of mice in animal experiments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211199403.4A CN115414391B (en) | 2022-09-29 | 2022-09-29 | Application of lactobacillus plantarum MA2 in preparation of medicine for preventing or improving adenine-induced chronic kidney disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211199403.4A CN115414391B (en) | 2022-09-29 | 2022-09-29 | Application of lactobacillus plantarum MA2 in preparation of medicine for preventing or improving adenine-induced chronic kidney disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115414391A true CN115414391A (en) | 2022-12-02 |
| CN115414391B CN115414391B (en) | 2024-03-19 |
Family
ID=84206627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211199403.4A Active CN115414391B (en) | 2022-09-29 | 2022-09-29 | Application of lactobacillus plantarum MA2 in preparation of medicine for preventing or improving adenine-induced chronic kidney disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115414391B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116064333A (en) * | 2023-02-14 | 2023-05-05 | 北京三元食品股份有限公司 | Breast milk source lactobacillus plantarum, and product and application thereof |
| CN116694503A (en) * | 2023-03-27 | 2023-09-05 | 上海华聿康生物科技有限公司 | Lactobacillus plantarum Lp-HZ55 with bowel relaxing and immunity improving functions |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329884A (en) * | 2020-02-18 | 2020-06-26 | 天津科技大学 | Application of lactobacillus plantarum BC299 in medicines and foods for treating inflammatory bowel diseases and psychogenic problems |
| CN112386614A (en) * | 2020-11-25 | 2021-02-23 | 天津科技大学 | Application of lactobacillus plantarum MA2 in preparation of medicine or food for preventing or improving Alzheimer's disease |
| CN112553115A (en) * | 2020-12-23 | 2021-03-26 | 南昌大学 | Application of lactobacillus plantarum ZDY2013 in preparation of products for relieving kidney injury |
| CN114507621A (en) * | 2022-02-23 | 2022-05-17 | 华南理工大学 | Lactobacillus plantarum and application thereof in aspects of reducing uric acid, losing weight and resisting inflammation |
-
2022
- 2022-09-29 CN CN202211199403.4A patent/CN115414391B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329884A (en) * | 2020-02-18 | 2020-06-26 | 天津科技大学 | Application of lactobacillus plantarum BC299 in medicines and foods for treating inflammatory bowel diseases and psychogenic problems |
| CN112386614A (en) * | 2020-11-25 | 2021-02-23 | 天津科技大学 | Application of lactobacillus plantarum MA2 in preparation of medicine or food for preventing or improving Alzheimer's disease |
| CN112553115A (en) * | 2020-12-23 | 2021-03-26 | 南昌大学 | Application of lactobacillus plantarum ZDY2013 in preparation of products for relieving kidney injury |
| CN114507621A (en) * | 2022-02-23 | 2022-05-17 | 华南理工大学 | Lactobacillus plantarum and application thereof in aspects of reducing uric acid, losing weight and resisting inflammation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116064333A (en) * | 2023-02-14 | 2023-05-05 | 北京三元食品股份有限公司 | Breast milk source lactobacillus plantarum, and product and application thereof |
| CN116694503A (en) * | 2023-03-27 | 2023-09-05 | 上海华聿康生物科技有限公司 | Lactobacillus plantarum Lp-HZ55 with bowel relaxing and immunity improving functions |
| CN116694503B (en) * | 2023-03-27 | 2024-01-05 | 上海华聿康生物科技有限公司 | Lactobacillus plantarum Lp-HZ55 with bowel relaxing and immunity improving functions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115414391B (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110964650B (en) | Bacterial strain for preventing and treating metabolic diseases and application thereof | |
| US7901925B2 (en) | Lactobacillus delbrueckii ssp. bulgaricus strain and compositions | |
| CN115414391A (en) | Application of lactobacillus plantarum MA2 in preparation of medicine for preventing or improving adenine-induced chronic kidney diseases | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| TWI731279B (en) | Lactobacillus fermentum gkf3, composition containing the same and its use for improving psychataxia | |
| CN102935092B (en) | Novel lactobacilli and composition thereof, and application thereof in preparing medicines used for ameliorating diabetes and complications thereof | |
| CN111346114A (en) | Application of lactobacillus reuteri | |
| CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| MX2012009945A (en) | Lactic acid bacterium-containing preparation. | |
| CN111575204B (en) | Lactobacillus paracasei capable of relieving or treating allergic diseases and application thereof | |
| CN115887483A (en) | Application of lactobacillus fermentum CECT5716 exopolysaccharide in preparation of medicines for preventing or improving chronic kidney diseases | |
| CN111329884A (en) | Application of lactobacillus plantarum BC299 in medicines and foods for treating inflammatory bowel diseases and psychogenic problems | |
| CN116731891A (en) | Bifidobacterium breve B2798 and application thereof in preparation of probiotic preparation | |
| KR100918629B1 (en) | Composition for prevention or treatment of liver toxicity comprising lactic acid bacteria fermented Ssangwhatang | |
| CN117286078B (en) | Lactobacillus plantarum for improving gastrointestinal health and application thereof | |
| CN109207389B (en) | Thrombolytic lipid-lowering probiotic compound bacteria traditional Chinese medicine oral liquid and preparation method thereof | |
| CN111035658A (en) | Use of pediococcus pentosaceus | |
| CN111035661A (en) | Application of lactobacillus plantarum | |
| KR100988923B1 (en) | Composition for alleviation of alcohol-induced hangover comprising lactic acid bacteria fermented Ssangwhatang | |
| JP6761268B2 (en) | MKP-1 inducer | |
| WO2008002484A2 (en) | Novel lactobacillus bulgaricus strain and compositions | |
| CN110839693B (en) | Application of parabacteroides gibsonii in preventing or treating obesity or related diseases | |
| KR20180125895A (en) | Composition with Lactobacillus sp. KCCM 11826P for preventing, treating or improving disease from uremic toxins | |
| CN109674060B (en) | Probiotic dietary supplement with auxiliary function of relieving type II diabetes and application thereof | |
| CN113116941A (en) | Probiotics and prebiotics compound preparation capable of relieving type 2 diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |